Acceleron Named a “Most Honored” Company in Institutional Investor 2020 “All-America Executive Team” Rankings

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that it has been included in the recently released Institutional Investor 2020 All-America Executive Team rankings as one of the countrys Most Honored companies.

Institutional Investor is widely considered the leading publication for institutional investors, including money managers and pension fund managers. Each year, the publication releases its All-America Executive Team rankings, which reflect extensive polling of investment professionals to name the best CEOs, CFOs, and investor relations (IR) teams. The 2020 rankings are based on the opinions of nearly 1,700 portfolio managers, buy-side analysts, and sell-side analysts. This year, nearly 1,500 companies across a wide range of sectors received votes in the Institutional Investor polling process, of which only 147 companies were deemed Most Honored.

Were pleased to be named a ˜Most Honored company in the latest Institutional Investor rankings, alongside some of this countrys largest, best-known enterprises, said Habib Dable, President and Chief Executive Officer of Acceleron. This recognition is a reflection of our concerted effort as a team to communicate our growth strategy in as transparent, responsive, and accessible fashion as possible to the investor and analyst communities.

Companies earning the Most Honored designation had to receive two or more top-three appearances in the categories of Best CEO, CFO, IR Professional, and IR Program. Acceleron was also recognized for its overall IR program as well as for its performance in metrics of environmental and social responsibility.

About Acceleron

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body’s ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Bristol-Myers Squibb, are co-promoting newly approved REBLOZYL (luspatercept-aamt), the first and only approved erythroid maturation agent, in the United States and are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes and myelofibrosis. Acceleron is also advancing its neuromuscular program with ACE-083, a locally-acting Myostatin+ agent in Phase 2 development in Charcot-Marie-Tooth disease and is conducting a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.

For more information, please visit Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

Acceleron Pharma Inc.


Todd James, IRC, (617) 649-9393

Vice President, Investor Relations and Corporate Communications

Ed Joyce, (617) 649-9242

Director, Investor Relations


Matt Fearer, (617) 301-9557

Director, Corporate Communications